Search / Trial NCT06225609

No Stoma VS Ghost Stoma in Patients Undergoing Total Mesorectal Excision for Rectal Cancer

Launched by FAN LI · Jan 17, 2024

Trial Information

Current as of December 30, 2024

Not yet recruiting

Keywords

Ghost Ileostomy No Ileostomy Rectal Cancer

ClinConnect Summary

So far, there are no relevant reports on ghost ileostomy among the Asian population, and all studies are small sample studies.In the past decades, with the advent of circular stapling devices, many middle and low rectal cancers have chosen new sphincter-saving procedures (such as ISR and Ta TME). Nevertheless, when the incidence rate of AL remains high, is diverting ileostomy applicable? Is ghost ileostomy applicable to rectal cancer in the context of new surgical procedures such as pelvic floor reconstruction, perineal drainage, anastomotic reinforcement and robotic surgery? Is this delaye...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Pathologically confirmed rectal cancer.
  • age ≥18 years and ≤80 years.
  • intraoperative ghost ileostomy or no stoma was performed.
  • Exclusion Criteria:
  • ASA score \>3.
  • Patients with coexisting complete intestinal obstruction.
  • History of long-term use of immunosuppressive drugs or glucocorticoids.
  • Combined severe cardiac disease: with congestive heart failure or NYHA cardiac function ≥ grade 2.
  • Patients with a history of myocardial infarction or coronary artery surgery within 6 months before the procedure.
  • chronic renal failure (requiring dialysis or glomerular filtration rate \<30 mL/min).
  • Intraoperative combined multi-organ resection.
  • Combined cirrhosis of the liver.
  • Intraoperative findings of incomplete anastomosis and positive insufflation test.

About Fan Li

Fan Li is a dedicated clinical trial sponsor committed to advancing medical research and improving patient outcomes through innovative trial design and execution. With a focus on developing novel therapeutic solutions, Fan Li collaborates with leading researchers and healthcare professionals to ensure rigorous study protocols and adherence to regulatory standards. Leveraging a wealth of expertise in various therapeutic areas, the organization emphasizes transparency, ethical practices, and patient-centric approaches, ultimately striving to contribute to the evolution of healthcare and the discovery of impactful treatments.

Locations

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0